Cookie consent
AdvancedCardiacTherapies.ac.uk will set cookies on your device (either because they are necessary to make the site work and keep it secure, or if you give your consent). Cookies are small files that sit on your computer, phone or tablet. This information …
Governance
The MRC/BHF CoRE in Advanced Cardiac Therapies began on 1 January 2025, with a duration of 14 years. Funding has been secured for an initial 7 year period. An experienced leadership team are responsible for delivering CoRE research and impact. Day-to-day …
Opportunities
We are developing new opportunities for our academic and clinical members, and building partnerships with patient, healthcare and industry partners. Our events , job opportunities and PhD studentships are regularly updated. Further information will be …
Studentships
We are not currently advertising any PhD studentships. …
First annual symposium brings together growing REACT community
Members of the MRC/BHF CoRE in Advanced Cardiac Therapies (REACT) gathered in London last week for our first annual symposium. The meeting built on progress from our first year of operation and showcased the breadth of projects underway across the …
REACT Independent Strategic Advisory Board meets for the first time
The Independent Strategic Advisory Board (ISAB) for the MRC/BHF CoRE in Advanced Cardiac Therapies met for the first time in March 2026. The advisory board fulfils an important role as a sounding board and critical friends to our leadership …
Clinical translation
A comprehensive array of pre-clinical models will be utilised to test therapeutic leads generated by REACT. Existing targets will be fast tracked for safety and efficacy assessment in models of chronic heart failure conditions, and then prioritised for …
Our research
We aim to discover and target fundamental processes that drive heart failure and regulate cardiac regeneration. Our therapeutic products will leverage endogenous reparative processes to generate new heart muscle, promote vessel formation and resolve …
Cardiac delivery
We aim to achieve cardiac-specific targeting of vectors and nanoparticle-delivered nucleic acid medicines to minimise adverse effects and allow for effective, inducible and/or regulated expression of single or multiple target therapeutic nucleic acids. …
Professor Andy Baker
Andy is BHF Professor of Translational Cardiovascular Sciences and Gustav Born Chair of Vascular Biology at the University of Edinburgh. He has a long standing interest in the understanding of vascular pathophysiology. Andy's laboratory was set up with …